Attached files
| file | filename |
|---|---|
| S-1/A - FORM S-1/A - Anthera Pharmaceuticals Inc | f53438a1sv1za.htm |
| EX-1.1 - EXHIBIT 1.1 - Anthera Pharmaceuticals Inc | f53438a1exv1w1.htm |
| EX-10.5 - EXHIBIT 10.5 - Anthera Pharmaceuticals Inc | f53438a1exv10w5.htm |
| EX-10.4 - EXHIBIT 10.4 - Anthera Pharmaceuticals Inc | f53438a1exv10w4.htm |
| EX-10.18 - EXHIBIT 10.18 - Anthera Pharmaceuticals Inc | f53438a1exv10w18.htm |
| EX-10.16 - EXHIBIT 10.16 - Anthera Pharmaceuticals Inc | f53438a1exv10w16.htm |
| EX-10.17 - EXHIBIT 10.17 - Anthera Pharmaceuticals Inc | f53438a1exv10w17.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
consent to the use in this Amendment No. 1 to Registration Statement
No. 333-161930 of our
report dated September 15,
2009, (which report expresses an unqualified opinion on the financial statements and includes an
explanatory paragraph regarding the Company’s development stage status and its ability to continue
as a going concern) relating to the financial statements of Anthera Pharmaceuticals, Inc. appearing
in the prospectus which is part of this Registration Statement.
We
also consent to the reference to us under the heading
“Experts” in such prospectus.
/s/ Deloitte & Touche LLP
San Francisco, California
October 19, 2009